Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols

PharmacoEconomics

Volumn 14, Issue SUPPL. 3, 1998, Pages 29-38

  Cziraky, Mark ^a  

^a Health Core   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ADVERSE DRUG REACTION; CLINICAL PROTOCOL; CLINICAL TRIAL; DYSLIPIDEMIA; HUMAN; ISCHEMIC HEART DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; RANDOMIZED CONTROLLED TRIALS;

EID: 0032419117     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814003-00004     Document Type: Review

References (82)

1. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996; 124 Suppl.: S1-9
2. West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol 1997; 79: 756-62
3. Scandinavian Simvastian Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
4. Frick MH, Elo MO, Haapa K. et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
5. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74
6. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64
7. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81
8. Canner PL. Berge KG, Wender NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55
9. Pyörälä K, De Backer G. Graham I. et al. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and the European Society of Hypertension. Eur Heart J 1994; 15: 1300-31
10. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-445
11. Stelmach WJ, Rush DR, Brucker PC, et al. Diet and exercise and gemfibrozil therapy for the management of dyslipidemia. A CEN study. J Fam Pract 1993; 36: 401-8
12. Grover SA, Coupal L, Hu X-P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995; 274: 801-6
13. Jackson R, Beaglehole R. Evidence-based management of dyslipidaemia. Lancet 1995; 346: 1440-2
14. Pedersen TR. Lowering cholesterol with drugs and diet. N Engl J Med 1995; 333: 1350-1
15. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996: 348: 1339-42
16. Nawrocki JW, Weiss SR, Davidson MH. et al. Reduction of LDL cholesterol by 25% 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vase Biol 1995; 15: 678-82
17. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvaslatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-33
18. Farmer JA, Gotto Jr AM. Choosing the right lipid-regulating agent. A guide to selection. Drugs 1996; 52: 649-61
19. Spencer CM, Barradell LB. Gemfibrozil: a reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs 1996; 51: 982-1018
20. McClellan KJ, Wiseman LR, McTavish D. Cerivastatin. Drugs 1998; 55: 415-20
21. Witztum JL. Drugs used in the treatment of hyperlipoproteinemias. In: Hardman JG. Gilman AG. Limbird LE. editors. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill. 1996: 875-97
22. Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998; 82 (6): 737-43
23. Knopp RH, Alagona P, Davidson M. et al. Equivalent efficacy of a time-release form of niacin (Niaspan ) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998; 47 (9): 1097-104
24. Ruder Jl. Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92 (1): 77-81
25. O'Kane MJ, Trinick TR, Tynan MB. et al. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. Br J Clin Pharmacol 1992: 33 (4): 451-3
26. Tornvall P, Walldius G. A comparison between nicotinic acid and acipimox in hypertriglyceridaemia - effects on serum lipids, lipoproteins, glucose tolerance and tolerability. J Intern Med 1991; 230 (5): 415-21
27. Acipimox - a nicotinic acid analogue for hyperlipidaemia. Drug Ther Bull 1991; 29(15): 57-9
28. Barlow CW, Soicher ER, Jankelow D. et al. Safety, tolerability and efficacy of acipimox in type II hyperlipidaemia. S Afr Med J 1990; 77 (10): 504-5
29. Dart AM. Managing elevated blood lipid concentrations. Who, when and how? Drugs 1990; 39: 374-87
30. Ericsson CG, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-53
31. Report from the Committee of Principal Investigators. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-118
32. Tikkanen MJ. Statins: within-group comparisons, statin escape and combination therapy. Curr Opin Lipidol 1996; 7 (6): 385-8
33. Athyros VG, Papageorgiou AA. Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80 (5): 608-13
34. Smit JW, Jansen GH, de Bruin TW. et al. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am J Cardiol 1995; 76 (2): 126A-8
35. Wirebaugh SR, Shapiro ML, McIntyre TH. A retrospective review of the use of lipid-lowering agents in combination, specifically gemfibrozil and lovastatin. Pharmacotherapy 1992; 12: 445-50
36. Jokubaitis LA. Fluvastatin in combination with other lipid-lowering agents. Br J Clin Pract 1996; 77A Suppl.: 28-32
37. Shepherd J. Cobbe SM. Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
38. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
39. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
40. Ferguson JJ. Meeting highlights. Highlights of the 70th scientific sessions of the American Heart Association. Circulation 1998; 97 (13): 1217-20
41. Simes RJ, Baker S, MacMahon S, et al. Pravastatin reduces total mortality in patients with coronary heart disease and average cholesterol levels: relationship of baseline cholesterol and treatment effects in the LIPID trial. Presented at the 47th Annual Scientific Session of the American College of Cardiology; 1998 Mar 29-Apr 1: Atlanta, Georgia, USA
42. Blankenhorn DH, Azen SP, Kramsch DM, et al. The Monitored Atherosclerosis Regression Study (MARS): coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993; 119: 969-76
43. Jukema JE, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40
44. Pitt B, Mancini GB, Ellis SG, et al. Pruvastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995: 26 (5): 1133-9
45. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994, 89: 959-68
46. MAAS Investigators. Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet 1994; 344; 633-8
47. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-64
48. Furberg CD, Adams Jr HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events: Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679-87
49. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69 (2): 313-24
50. de Faire U, Ericsson CG, Grip L, et al. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. Cardiovasc Drugs Ther 1997: 11 Suppl. 1: 257-63
51. Ornish D, Brown SE, Scherwitz, LW, et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336: 129-33
52. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ideal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55
53. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98
54. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007-12
55. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40
56. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-9
57. Schuler G, Hambrecht R. Schlierf G, et al. Regular physical exercise and low-fat diet. Circulation 1992; 86: 1-11
58. Arntzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins, and the progression of atherosclerosis. N Engl J Med 1985; 312: 805-11
59. MacMahon S, Sharpe N, Gamble G. et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID Atherosclerosis substudy. Circulation 1498; 97: 1784-90
60. Pederson TR, Tobert JA, Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. A reappraisal. Drug Saf 1996; 14: 11-24
61. Bertolini S, Bon GB, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypereholesterolemia. Atherosclerosis 1997; 130: 191-7
62. Dart A, Jerums G. Nicholson G. et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39-44
63. Davidson M, McKenney J, Stein E. et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79; 1475-81
64. Farmer JA, Washington LC, Jones PH, et al. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther 1992; 14: 708-17
65. Lovaslatin Pravastatin Study Group. A multicenter comparative study of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993; 71: 810-5
66. Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993; 71: 1408-14
67. Jones P, Kafonek S, Laurora I. et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81: 582-7
68. Jungnickel PW, Cantral KA, Maloley PA, Pravastatin: a new drug for the treatment of hypereholesterolemia. Clin Pharm 1992; 11: 677-89
69. Tikkanen MJ, Bocanegra TS, Walker JF, et al. Comparison of low dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol: a multicenter study. Am J Med 1989; 87 Suppl. 4A: 47S-53
70. Tikkanen MJ, Helve E, Jäättelä A. et al. Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study. Am J Cardiol 1988; 62: 35J-43
71. Plosker GL. Wagstaff AJ. Fluvaslatatin. A review of its pharmacology and use in the management of hypercholeslevolaemia. Drugs 1996; 51: 433-59
72. Plosker GI., McTavish D. Sinivastatin. A reappraisal of its pharmacology und therapeutic efficacy in hypercholesterolaemia. Drugs 1995; 50: 334-63
73. Stein EA, Davidson MH. Dufovne CA. et al. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther 1996; 1: 107-16
74. McKenney JM, McCormick LS. Weiss S, et al. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. Am J Med 1998; 104 (2): 137-43
75. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81 Suppl. 4A: 66B-9B
76. Lea AP, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997; 53: 828-47
77. Illingworth DR. Clinical implications of new drugs for lowering plasma cholesterol concentrations. Drugs 1991; 41: 151-60
78. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safely profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998; 158: 577-84
79. Haria M, McTavish D. Pravastalin, A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997; 53: 299-336
80. International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society. Nut Metab Cardiovase Dis 1992; 2: 113-56
81. Pierce I.R. Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-5
82. Assmann G. Schulte H, von Eckardstein A, Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-84